Shanghai [China], November 12 (ANI): Vice President of Shanghai Pharmaceuticals Li Dongming said on Tuesday ... also problems ...

As the COVID-19 pandemic clearly demonstrated, health is an integral part of Europe’s security. That principle underpinned a ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

The pharma churn is real, and new products are a constant need ... Pfizer’s vaccine franchise is under the gun, and not just ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...

With COVID-19, the rates are set to dip below those ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...

The global outbreak of COVID-19 has forced businesses to radically ... In the US, TV advertising for pharma products is still a big business, but this is mainly aimed at patients.

Kennedy’s role is expected to be far-reaching and extend into reshaping how vaccines are regulated, since he has emerged in ...

Analyst Charles Rhyee of TD Cowen maintained a Buy rating on Cencora (COR – Research Report), with a price target of $288.00. Charles ...

Pharma stocks generally offer investors ... Pfizer predicts that new products outside of the coronavirus business should contribute $20 billion to 2030 revenue. The acquisition of oncology ...